Oral candidiasis in HIV+ patients under treatment with protease inhibitors

AUTOR(ES)

Witzel, Andréa Lusvarghi, Silveira, Fernando Ricardo Xavier da, Pires, Maria de Fátima Costa, Lotufo, Mônica Andrade

FONTE

Brazilian Oral Research

DATA DE PUBLICAÇÃO

2008-12

RESUMO

The purpose of this work was to evaluate the influence of Protease Inhibitors (PI) on the occurrence of oral candidiasis in 111 HIV+ patients under PI therapy (Group A). The controls consisted of 56 patients that were not using PI drugs (Group B) and 26 patients that were not using any drugs for HIV therapy (Group C). The patient's cd4 cell counts were taken in account for the correlations. One hundred and ninety three patients were evaluated. The PI did not affect the prevalence of oral candidiasis (p = 0.158) or the frequency of C. albicans isolates (p = 0.133). Patients with lower cd4 cell counts showed a higher frequency of C. albicans isolates (p = 0.046) and a greater occurrence of oral candidiasis (p = 0.036).

Documentos Relacionados

• Clinical and laboratorial features of oral candidiasis in HIV-positive patients
• Protease inhibitors and azolic antifungals in HIV patients with histoplasmosis: a clinical pharmacokinetics perspective
• Comparison of oral fluconazole and clotrimazole troches as treatment for oral candidiasis in patients infected with human immunodeficiency virus.
• Oral Lactoferrin Treatment of Experimental Oral Candidiasis in Mice
• Xerostomy, dental caries and periodontal disease in HIV+ patients